IDT relocates to Sunnyvale to accelerate precision oncology innovation
Integrated DNA Technologies (IDT) announced the relocation of its original Bay Area site from Redwood City to Sunnyvale. The strategic move is part of IDT’s broader strategy to expand its research, development, and innovation capabilities to support market growth in precision oncology, including the minimal residual disease (MRD) and multi-cancer early detection (MCED) markets.
The 12,000-square-foot facility in Sunnyvale will feature state-of-the-art laboratory and office space designed to foster greater innovation, enhance research and development initiatives, and deepen collaboration opportunities with partners. Planned improvements in 2026 will further expand the space to support future growth.
As part of this strategic move, IDT has appointed Steven Henck, PhD, as Chief Technology Officer—a homecoming for a next generation sequencing (NGS) pioneer whose career has shaped the future of sequencing technologies. In this new capacity, Henck will engineer IDT’s transformative synthesis technologies and steer the company in driving the next wave of NGS and molecular biology innovation. Since joining IDT in 2019 as vice president of R&D, Henck most recently advanced to the CTO office at Danaher Life Sciences Omics Solutions Group as NGS Fellow, leveraging his nearly 30-year track record to drive high-throughput platforms for drug discovery, protein engineering, and antibody development.
Last year, IDT installed an innovation nexus, which will also transition to the Sunnyvale location. The innovation nexus serves as a collaboration center that enables IDT to innovate with regional customers, forge strategic partnerships, and drive R&D initiatives with leading-edge biotechnology companies. The innovation nexus also enables the transformation of IDT’s technical capabilities, building on its legacy portfolio and proven expertise in oligo synthesis technologies. This includes acquiring emerging and transformative synthesis technologies ranging from novel chemistries, enzymatic synthesis, and alternative platforms, to drive market growth in precision oncology research through advanced next generation sequencing applications and high-throughput approaches.
The new Sunnyvale site, located on E. Caribbean Dr. on the Cepheid campus, another Danaher Company, positions IDT closer to key industry partners and joint ventures, and will serve as a hub for scientific excellence and strategic alliance. IDT’s Redwood City office closed at the end of 2025.
